FindTrial
Sign In

Multi-Center, Parallel-Group, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety and Efficacy of Oral Lubiprostone in Patients with Chronic Idiopathic Constipation

Multi-Center, Parallel-Group, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety and Efficacy of Oral Lubiprostone in Patients with Chronic Idiopathic Constipation

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220460
Enrollment
Unknown
Registered
2007-11-01
Start date
2007-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Idiopathic Constipation

Interventions

investigational material(s) Generic name etc : lubiprostone INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for Inv

Sponsors

Sucampo Pharma, Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult chronic idiopathic constipation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy, Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026